Conferences  >  Medicine & Healthcare  >  Pharmacology and Drug Development  >  Canada

Xtalks

These past few years have marked the acceleration of the adoption of in silico techniques for more efficient and innovative clinical research. When embarking on a new R&D program, scientists face a strategic imperative to assemble the best and most relevant available data and insights. Jinkō, Novadiscovery’s in silico clinical trial simulation platform, has been designed to build and maintain a high-quality knowledge repository, allowing teams to seamlessly cooperate, both internally and with external thought leaders. During the first part of this webinar, featured speaker Dr. Friehs, will explain her role and how she uses jinkō with her fellows to extract, classify and qualify pieces of knowledge in a systematic, transparent and traceable manner, and use these in research reports and literature reviews. After that, featured speaker Frédéric (CPO of Novadiscovery) will showcase how this knowledge is then leveraged directly within jinkō to help lower cost and ethical constraints as well as achieve greater trial efficiency through the design and simulation of in silico trials. This will be illustrated with two practical use cases using Nova’s non-small cell lung cancer (NSCLC) disease model of epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma (LUAD). First, by exploring a large range of doses and then by testing eligibility criteria refinement and its impact on treatment effectiveness. Join this webinar to learn more about using a clinical trial simulation platform to generate auditable and reproducible digital evidence.

Xtalks;     Email: xtalks@dryfta.com

Pharma, Pharmacy

Regulation in Medicine and Pharmacology,    Pharmacogenomics, Personalized Medicine

Xtalks

The value of real-world data is clear. The acceptance of real-world evidence (RWE) is growing. But is this enough to propel RWE from being a nice-to-have to a must-have? PicnicHealth is hosting a four-part webinar series to reframe the “ROI” for RWE generation and tackle the question: beyond the return on investment for RWE, what is the risk of inaction? This webinar will explore relevant examples of how Data Science and Digital Health are accelerating pharmaceutical innovation and driving impact for patients. Bringing together global experts with diverse perspectives spanning regulatory, R&D and health tech, this conversation will highlight innovative, RWD-driven approaches to drug development and regulatory decision-making. Speakers will discuss the need for different types of data to construct a complete clinical picture – and how a data-driven approach can drive impact across both research and clinical practice. Register today to learn more about the transformational value of real-world data for drug development and regulatory decision-making.

Xtalks;     Email: xtalks@dryfta.com

Pharma

Optica

Focuses on the convergence in these rapidly evolving areas, spanning from basic biology to clinical diagnostics and therapeutic applications. This multidisciplinary topical meeting will highlight recent advances in these rapidly evolving areas with a goal of stimulating novel strategies for molecular probe development, site-specific drug delivery, monitoring treatment response and clinical translation to improve diagnosis or treatment of diseases. Areas to be covered include, but are not limited to, novel molecular probe design, applications of smart molecular probes in basic and applied research, endogenous and exogenous optical molecular biomarkers, multimodal imaging, advances in instrumentation and algorithms for optical molecular imaging, molecular and functional imaging of normal and diseased tissue, image-guided drug delivery, drug screening and monitoring therapeutic response.

Photonics, Optoelectronics and Display Devices,    Healthcare Technologies